High-Dose Statin Therapy, Value for Older Adults

September 2007
Travel Medicine Advisor;Sep2007, Vol. 17 Issue 9, p1
The article focuses on the findings of a study on the potential significance of high-dose statin therapy in older people with stable coronary disease conducted in the U.S. Patients who received low-dose atorvastatin achieved average cholesterol levels of 100 mg/dl versus 70 mg/dl for high dose therapy. Adverse events associated with the therapy include resuscitated cardiac arrest. Those treated with high-dose atorvastatin were found to have a 2.3 percent absolute risk reduction.


Related Articles

  • Comprehensive lipid-lowering update: Part 2: Who needs lipid-lowering drugs? LaRosa, John C.; McGowan, Mary P.; Weart, C. Wayne // Patient Care for the Nurse Practitioner;Mar2006, Vol. 9 Issue 3, p1 

    The article discusses the use of lipid-lowering drugs in the treatment of coronary heart disease. Statins or other lipid-lowering drugs should be prescribed only in a setting of lifestyle modifications. The choice of a first statin will depend on three main factors: the patient's risk level, the...

  • Hyperlipidaemia --part one.  // GP: General Practitioner;11/18/2002, p47 

    Reports that lowering total cholesterol is effective in the prevention of coronary heart diseases (CHD). Significance of statins in preventing coronary diseases; Primary and secondary prevention of CHD; Role of lovastatin in preventing CHD.

  • Is the health of your heart in the 'HANDS OF ALL-STATINS?' Deas, Gerald W. // New York Amsterdam News;6/2/2005, Vol. 96 Issue 23, p30 

    This article reports that there are a group of drugs that actually have been given a "coronation." That is, they have been hailed as the drugs that will prevent blockage of the coronary arteries, and now they are king of all drugs having to do with preventing heart attacks. They are also thought...

  • Statin induced temporary accommodation inertia - a report. Chakrabarti, Arun; Sengupta, Gairik; Basu, Pallab; Misra, Ruby // Asian Journal of Pharmaceutical & Health Sciences;Jan-Mar2013, Vol. 3 Issue 1, p583 

    Statin medications are mainstay of treatment for patients with dyslipidemia and coronary artery diseases. Statin has rarely some adverse effects like rhabdomyolysis and myositis. There are several reported cases of eye muscle weakness or paralysis leading to diplopia, ophthalmoplegia and...

  • Who needs lipid-lowering drugs?  // Patient Care;Mar2006, Vol. 40 Issue 3, p38 

    Focuses on the availability of statin therapy for reducing low density lipoproteins cholesterol in patients with coronary heart disease in the U.S. Benefits provided by such therapy demonstrated in clinical trials; Side effects of statin therapy; Options for patients who consider to start or...

  • The Effect of Atorvastatin on Liver Function among Patients with Coronary Heart Disease in Gaza Strip. Taleb, Mahmmoud H.; Almasri, Ihab M.; Siam, Naima I.; Najim, Ahmed A.; Ahmed, Adham I. // Pharmacology & Pharmacy;Jul2014, Vol. 5 Issue 8, p781 

    Statins, which are inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, are considered as one of the most important drugs and the drug of choice for reducing an abnormal cholesterol level. Statins are normally used to decrease the risk of coronary heart disease (CHD), but they tend...

  • Statin-induced liver disease a "myth.".  // Reactions Weekly;12/4/2010, Issue 1330, p3 

    The article discusses a research study on the safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver function, published in the November 24, 2010 issue of the journal "The Lancet."

  • Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels. Kumai, T.; Matsumoto, N.; Koitabashi, Y.; Takeba, Y.; Oonuma, S.; Sekine, S.; Tadokoro, M.; Kobayashi, S. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jul2005, Vol. 3 Issue 3, p195 

    The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are considered first-line therapeutic agents for the prevention of coronary heart disease and atherosclerotic disorders related to hypercholesterolemia. Statins inhibit lipid deposition in the aortic endothelium. Although...

  • Why The Lipid Hypothesis Is Wrong.  // Health & Stress;Dec2012, Vol. 24 Issue 12, p7 

    The article outlines the author's presentation about statins as the solution for inflammation caused by coronary heart disease. The said presentation aims at explaining that inflammation was more likely to be the result of atherosclerosis plaque and the coronary atherosclerosis was not due to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics